& Litwin, J
Now, it's time for policymakers, employers and insurers to work with pharmaceutical companies to ensure no one is left behind in receiving the care they deserve and need." In a clinical study, tirzepatide 5mg, along with a reduced calorie diet and increased physical activity, achieved an average of 15% weight loss over 72 weeks compared to 3.1% for placebo
1) Volume loss (the deflated look) Common areas: temples, midface, under-eye hollowness, around the mouth, jawline
However, the potential downside is that, in the process of losing fat, individuals may also lose lean muscle mass, especially if they are in a calorie deficit
A recent report covered that tirzepatide increased adiponectin levels and significantly decreased Nash related biomarkers, which was beneficial to improve NAFLD (197)